Mylan Inc. (MYL) said Meridian Medical Technologies, a Pfizer (PFE) subsidiary, has entered into a settlement agreement with Teva (TEVA) that will resolve pending patent litigation related to its abbreviated new drug application for a generic epinephrine auto-injector.
According to the settlement terms, Teva may launch a generic epinephrine auto-injector covered by its ANDA on June 22, 2015 or earlier under certain circumstances, subject to receipt of approval from the U.S. Food and Drug Administration. Teva currently does not have tentative approval from the FDA for its epinephrine auto-injector product.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org